In February, the Food and Drug Administration issued a draft guidance, “Good Reprint Practices,” that would allow drug and device companies some leeway in off-label promotion. The guidance would permit companies to give doctors reprints of articles from medical journals about unapproved uses of drugs and devices, within certain parameters. The proposal is similar to guidelines that were in effect since the late 1990s, but expired in 2006.
Register to view the full article
Register for MeetingsNet.com and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.
0 comments
Hide comments